Concepedia

Rosa L. Frias

RL

Statistics

Publications

9

Citations

2K

H-Index

9

Active since

2014

Affiliations

Harvard University(Current)

Massachusetts General Hospital

Institut Gustave Roussy

Université Paris-Saclay

Centre National de la Recherche Scientifique

Rosa L. Frias is an author at Harvard University specializing in medicine, oncology, and molecular oncology.

Publications per year

2014–2023

9

Publications

9

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Adam Crystal, Alice T. Shaw, Lecia V. Sequist et al. · Science · 2014 · 733 citations

, , +17

Resensitization to Crizotinib by the Lorlatinib<i>ALK</i>Resistance Mutation L1198F

Alice T. Shaw, Luc Friboulet, Ignaty Leshchiner et al. · New England Journal of Medicine · 2015 · 484 citations · Full text

, , +16

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Helen Y. Zou, Luc Friboulet, David P. Kodack et al. · Cancer Cell · 2015 · 463 citations · Full text

, , +14

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti et al. · Clinical Cancer Research · 2019 · 167 citations · Full text

, , +16

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC

Joao V. Alessi, Arielle Elkrief, Biagio Ricciuti et al. · Journal of Thoracic Oncology · 2023 · 91 citations · Full text

, , +16

1–5 of 9